source
- Cloudbreak Pharma’s Phase 3 Eye Drop Shows Significant Benefit in Pterygium TrialCloudbreak Pharma reported that its phase 3 trial of CBT-001, a multi‑kinase inhibitor eye drop for pterygium, met both co‑primary endpoints. The study compared two doses of CBT-001 given twice da…
- STAT+: Beyond statins, one drug lowered heart attack risk by 20%A new study could help doctors figure out what medicine to prescribe for cholesterol when statins don't cut it: It's “answering a really challenging clinical question."